Novo Nordisk A/S
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
Inclusion Criteria: 1. Male or female (sex at birth). 2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported): * For Japanese participants: both parents of Japanese descent. * For Chinese participants: both parents of Chinese descent. * For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia). 3. Age at the time of signing the informed consent: 1. For Part A: 18-55 years (both inclusive) 2. For Part B: 18-65 years (both inclusive) 3. For Part C: 18-55 years (both inclusive). 4. BMI at screen…
UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.
Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.
Arctuva estimate
Verify or correct the compensation shown for this listing.